The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Prior anti-CD38 exposure and outcomes with isatuximab in R/R multiple myeloma
Albert Oriol, MD, PhD, Josep Carreras Leukaemia Research Institute, Barcelona, Spain, discusses a post-hoc analysis of the IRAKLIA study (NCT05405166) evaluating isatuximab, pomalidomide and dexamethasone according to prior anti-CD38 antibody exposure for relapsed/refractory (R/R) multiple myeloma. He highlights lower efficacy following prior anti-CD38 treatment, with outcomes improving as the interval between exposures increased, suggesting that alternative treatment targets may be preferable when available. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
